Regeneron (REGN) Draws Higher Target From TD Cowen

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 13 Companies that Just Started Paying Dividends.

During the Q4 2025 earnings call, CEO Leonard Schleifer said Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) delivered steady revenue growth. Fourth-quarter sales rose 3% from a year earlier. He said the increase came from double-digit growth across three key products.

Global net sales of DUPIXENT climbed 32%. LIBTAYO sales increased 13% on a constant-currency basis. In the U.S., EYLEA HD stood out, with sales up 66%. Schleifer pointed to that performance as a clear sign of momentum, particularly in the domestic market.

He described DUPIXENT as a core pillar of the business. The drug is now used by more than 1.4 million patients worldwide and remains positioned for further growth. Schleifer also highlighted progress at LIBTAYO, citing strength in adjuvant CSCC and rising share in advanced non-small cell lung cancer. In the U.S., he said the therapy has become the second most prescribed immunotherapy in the first-line setting.

Looking ahead, Schleifer laid out a busy regulatory and development agenda. He said the company expects at least four FDA approvals, including three new molecular entities across different modalities, along with approval of the EYLEA HD prefilled syringe.

He also noted plans to launch 18 additional Phase III studies over the coming years, with total enrollment of about 35,000 patients. According to Schleifer, the scale of investment is intended to support the next wave of potential blockbuster products.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases.

READ NEXT: 13 Best February Dividend Stocks To Buy and 14 High Yield Dividend Stocks with Sustainable Payouts

Disclosure: None.